- Home
- RMBI vs CGTX Comparison
RMBI vs CGTX Comparison
Compare RMBI & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RMBI | CGTX |
|---|---|---|
| Founded | 1887 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.3M | 132.4M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RMBI | CGTX |
|---|---|---|
| Price | $14.32 | $1.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | 11.4K | ★ 971.4K |
| Earning Date | 01-22-2026 | 03-19-2026 |
| Dividend Yield | ★ 4.18% | N/A |
| EPS Growth | ★ 27.17 | N/A |
| EPS | ★ 1.17 | N/A |
| Revenue | ★ $46,756,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.26 | ★ N/A |
| Revenue Growth | ★ 8.95 | N/A |
| 52 Week Low | $11.37 | $0.22 |
| 52 Week High | $15.24 | $3.83 |
Technical Indicators
Market Signals| Indicator | RMBI | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.49 | 29.50 |
| Support Level | $13.72 | $1.08 |
| Resistance Level | $14.28 | $1.18 |
| Average True Range (ATR) | 0.31 | 0.09 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 89.71 | 4.00 |
Price Performance
Historical ComparisonAbout RMBI Richmond Mutual Bancorporation Inc.
Richmond Mutual Bancorp Inc is a United States-based banking company. Its principal business consists of attracting deposits from the general public & brokered deposits and investing those funds predominantly in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one-to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans. The company has one reportable segment which is Community Banking.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.